Yosuke Fujimoto, Yuichi Fujita, Kazuhiro Tanaka, Hiroaki Nagashima, Shunsuke Yamanishi, Yusuke Ikeuchi, Hirofumi Iwahashi, Shoji Sanada, Yoshihiro Muragaki, Takashi Sasayama. Clinical Benefits of Photodynamic Therapy Using Talaporfin Sodium in Patients With Isocitrate Dehydrogenase-Wildtype Diagnosed Glioblastoma: A Retrospective Study of 100 Cases. Neurosurgery. 2024
Shunsuke Yamanishi, Hiroaki Nagashima, Kazuhiro Tanaka, Takiko Uno, Yusuke Ikeuchi, Hirofumi Iwahashi, Mitsuru Hashiguchi, Shintaro Horii, Tomoo Itoh, Yoshihiro Muragaki, et al. Association of preoperative seizures with reduced expression of soluble CD163, an M2 macrophage marker, in the cerebrospinal fluid in isocitrate dehydrogenase wild-type glioblastoma. Journal of neuro-oncology. 2024
Takashi Sasayama, Takeshi Hamada, Kazuhiro Tanaka, Hiroaki Nagashima, Shunsuke Yamanishi, Takehiko Ueyama. Potential of GSPT1 as a novel target for glioblastoma therapy. Cell Death & Disease. 2024. 15. 8
Avishay Spitzer, Simon Gritsch, Masashi Nomura, Alexander Jucht, Jerome Fortin, Ramya Raviram, Hannah R Weisman, L Nicolas Gonzalez Castro, Nicholas Druck, Rony Chanoch-Myers, et al. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer cell. 2024. 42. 5. 904-914
Ali M Nasser, Lisa Melamed, Ethan Wetzel, Chia-Chen Chang, Hiroaki Nagashima, Yosuke Kitagawa, Logan Muzyka, Hiroaki Wakimoto, Daniel P Cahill, Julie J Miller. CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024
Magnetic resonance spectroscopy of glutamate and 2-hydroxyglutarate in patients with the IDH1 mutant glioma: A prospective validation study
(22nd International Conference on Brain Tumor Research and Therapy (ICBTRT) 2018)